EARLY CLINICAL TRIALS EXPERTISE
Recent oral presentations
ASCO 2015
• Antitumor activity and safety of
pembrolizumab in patients with PD-L1
positive advanced ovarian cancer: Interim
results from a phase Ib study
ECC 2015
• Activity of rociletinib in EGFR mutant
NSCLC patients with a history of CNS
involvement
Recent publications
• Helissey C, Biondani P, Roquet F,
Lanoy E, Mir O, Varga A, Massard C,
Gazzah A, Ribrag V, Bahleda R, PostelVinay S, Angevin E, Deutsch E, Soria JC,
Hollebecque A. Patients aged over 75
years enrolled in phase I clinical trials:
The gustave roussy experience.
Int J Cancer. 2015 (in press).
• Morschhauser F, Terriou L, Coiffier
B, Bachy E, Varga A, Kloos I, Lelievre H,
Sarry AL, Depil S, Ribrag V. Phase 1 study
of the oral histone deacetylase inhibitor
abexinostat in patients with Hodgkin
lymphoma, non-Hodgkin lymphoma, or
chronic lymphocytic leukaemia. Invest
New Drugs. 2015;33 (2):423-431.
• Morschhauser F, Terriou L, Coiffier
B, Bachy E, Varga A, Kloos I, Lelièvre H,
Sarry AL, Depil S, Ribrag V. Phase 1 study
of the oral histone deacetylase inhibitor
abexinostat in patients with Hodgkin
lymphoma, non-Hodgkin lymphoma, or
chronic lymphocytic leukaemia. Invest
New Drugs. 2015; 33(2):423-31.
• Bahleda R, Sessa C, Del Conte G,
Gianni L, Capri G, Varga A, Oprea C,
Daglish B, Hospitel M, Soria JC. Phase
I clinical and pharmacokinetic study
of ombrabulin (AVE8062) combined
with cisplatin/docetaxel or carboplatin/
paclitaxel in patients with advanced solid
tumors. Invest New Drugs. 2014; 32(6)
: 1188-96.
• Cousin S, Hollebecque A, Koscielny
S, Mir O, Varga A, Baracos VE, Soria
JC, Antoun S. Low skeletal muscle
is associated with toxicity in patients
included in phase I trials. Invest New
Drugs. 2014; 32(2):382-7.
• Hollebecque A, Deutsch E, Massard
C, Gomez-Roca C, Bahleda R, Ribrag V,
Bourgier C, Lazar V, Lacroix L, Gazzah A,
Varga A, de Baere T, Beier F, Kroesser
S, Trang K, Zenke FT, Klevesath M,
Soria JC. A phase I, dose-escalation
study of the Eg5-inhibitor EMD 534085
in patients with advanced solid tumors
or lymphoma. Invest New Drugs. 2013;
31(6):1530-8.
Andrea Varga
MD
General background
Andrea Varga, MD, Senior Medical Oncologist in the Drug
Development Department of Gustave Roussy Cancer
Campus since 2011. She received her medical degree
from Medical Faculty Cluj-Napoca Rumania in 2004.
She started her training in Medical Oncology at ClujNapoca University (2005-2010) in oncology, cardiology,
internal medecine and radiology units ,then at Paul
Brousse Hospital in Paris (2008-2009) and breast cancer
unit of Institut Gustave Roussy (2009-2010).
She continued her clinical research residency at IGR
(2009-2010) and became medical oncologist of phase I Unit
(Pr Soria) in 2011. Dr Varga is board-certified in Medical
Oncology since 2010.
Her research interests include phase I trials, drug
development, targeted and personalized therapy of breast
cancer, lung and other solid tumors.
•Hollebecque A, Deutsch E, Massard
C, Gomez-Roca C, Bahleda R, Ribrag V,
Bourgier C, Lazar V, Lacroix L, Gazzah A,
Varga A, de Baere T, Beier F, Kroesser
S, Trang K, Zenke FT, Klevesath M,
Soria JC. A phase I, dose-escalation
study of the Eg5-inhibitor EMD 534085
in patients with advanced solid tumors
or lymphoma. Invest New Drugs. 2013;
31(6):1530-8
29